1. A 78-year-old woman with chronic constipation and stage 3 chronic kidney disease (CKD, reduced kidney filtering function) needs a long-term laxative. Her physician selects polyethylene glycol (PEG) 3350. Which property of PEG 3350 best explains why it is effective and safe in this patient?
A) It is fermented by colonic bacteria into short-chain fatty acids that lower luminal pH
B) It stimulates the myenteric plexus (the nerve network controlling intestinal motility) directly to increase propulsive contractions
C) It is a non-absorbed, non-metabolized polymer that passes through the gut intact while retaining an obligate osmotic water load
D) It is absorbed systemically and increases renal water excretion to soften stool
E) It activates type-2 chloride channels on intestinal epithelial cells to drive luminal fluid secretion
ANSWER: C
Rationale:
Option C is correct. PEG 3350 is a high-molecular-weight polymer that is neither absorbed nor metabolized; it transits the gastrointestinal (GI) tract intact while dragging an obligate water load by osmosis. This softens stool and increases luminal volume without significant systemic absorption or electrolyte shifts at standard doses, which is why it is appropriate for elderly patients and those with renal impairment.
Option A: Option A is incorrect. Fermentation to short-chain fatty acids with luminal pH lowering describes lactulose, a non-absorbable disaccharide, not PEG.
Option B: Option B is incorrect. Direct stimulation of the myenteric plexus describes stimulant laxatives such as senna and bisacodyl, not the inert osmotic action of PEG.
Option D: Option D is incorrect. PEG is essentially not absorbed systemically; its action is entirely intraluminal, and it does not work through renal water excretion.
Option E: Option E is incorrect. Activation of type-2 chloride (ClC-2) channels describes lubiprostone, a secretagogue, not PEG.
2. A patient started on lactulose for constipation reports significant bloating and flatulence after several days. Which mechanism best accounts for both lactulose's laxative effect and these adverse effects?
A) Colonic bacteria ferment the non-absorbable disaccharide into short-chain fatty acids and gases, lowering luminal pH and raising osmotic pressure
B) It binds bile acids in the intestinal lumen, preventing their reabsorption
C) It is converted by intestinal esterases to an active form that directly stimulates secretomotor neurons
D) It inhibits the sodium/hydrogen exchanger isoform 3 (NHE3), reducing sodium and water absorption
E) It absorbs water and swells within the colon, mechanically stretching the colonic wall
ANSWER: A
Rationale:
Option A is correct. Lactulose is a non-absorbable disaccharide that reaches the colon intact, where bacteria ferment it into short-chain fatty acids and gases. This lowers luminal pH and increases osmotic pressure, producing the laxative effect, while the gas generated during fermentation accounts for the characteristic bloating and flatulence that limit tolerability.
Option B: Option B is incorrect. Bile acid binding describes cholestyramine and other bile acid sequestrants, not lactulose.
Option C: Option C is incorrect. Esterase conversion to an active form that stimulates secretomotor neurons describes bisacodyl, a stimulant laxative.
Option D: Option D is incorrect. NHE3 inhibition describes tenapanor, not lactulose.
Option E: Option E is incorrect. Swelling to mechanically stretch the colonic wall describes bulk-forming laxatives such as psyllium, not the fermentation-based action of lactulose.
3. Senna is described as a prodrug. Which statement correctly characterizes how senna produces its laxative effect?
A) It is absorbed in the small intestine and acts systemically on colonic smooth muscle
B) It retains water in the lumen purely by osmotic force without any neural stimulation
C) It activates guanylate cyclase-C (GC-C) receptors on the luminal epithelial surface
D) Colonic bacteria metabolize sennosides into active anthranoid metabolites that stimulate the myenteric plexus and reduce colonic water absorption
E) It is a surfactant that allows water and lipids to penetrate the stool mass
ANSWER: D
Rationale:
Option D is correct. Sennosides A and B are prodrugs that are metabolized by colonic bacteria into active anthranoid metabolites. These metabolites stimulate the myenteric plexus (the enteric nerve network governing motility) and inhibit colonic water absorption, increasing propulsive motility with an onset of roughly 6 to 12 hours when taken orally.
Option A: Option A is incorrect. Senna is not absorbed in the small intestine to act systemically; activation occurs locally in the colon by bacterial metabolism.
Option B: Option B is incorrect. Purely osmotic water retention without neural stimulation describes osmotic laxatives such as PEG, not a stimulant laxative.
Option C: Option C is incorrect. GC-C receptor activation describes linaclotide and plecanatide, not senna.
Option E: Option E is incorrect. Surfactant action allowing water and lipid penetration of stool describes docusate, a stool softener.
4. A patient with mild functional constipation is started on psyllium for long-term maintenance. What counseling point is most important to prevent a serious adverse outcome with this agent?
A) Take it only at bedtime because its onset is within 30 minutes
B) Maintain adequate fluid intake, because insufficient hydration can cause luminal obstruction
C) Avoid all dairy products while taking it to prevent binding interactions
D) Expect black discoloration of the stool and tongue, which is harmless
E) Stop the drug immediately if any abdominal cramping occurs, as this signals ischemic colitis
ANSWER: B
Rationale:
Option B is correct. Bulk-forming laxatives such as psyllium absorb water and expand within the colon, stretching the colonic wall and stimulating peristalsis. They require adequate fluid intake to work safely; without sufficient hydration, the expanding mass can cause luminal obstruction, a particular concern in patients with motility disorders or strictures.
Option A: Option A is incorrect. Bulk-forming agents have a slow onset (roughly 12 to 72 hours), not 30 minutes, and bedtime-only dosing tied to rapid onset is not their profile.
Option C: Option C is incorrect. Dairy avoidance is not a relevant precaution for psyllium.
Option D: Option D is incorrect. Black discoloration of stool and tongue is characteristic of bismuth subsalicylate, not psyllium.
Option E: Option E is incorrect. Mild cramping does not signal ischemic colitis with a bulk-forming agent; ischemic colitis is a documented risk of alosetron, a 5-HT3 antagonist used in IBS-D.
5. Lubiprostone is classified as a secretagogue laxative. By what mechanism does it increase intraluminal fluid and accelerate intestinal transit?
A) It blocks 5-hydroxytryptamine type 3 (5-HT3) receptors on primary afferent neurons
B) It binds and sequesters bile acids in the intestinal lumen
C) It antagonizes peripheral mu-opioid receptors in the enteric nervous system
D) It is fermented to gases that osmotically draw water into the lumen
E) It activates type-2 chloride (ClC-2) channels on the apical surface of intestinal epithelial cells, driving chloride and water into the lumen
ANSWER: E
Rationale:
Option E is correct. Lubiprostone is a bicyclic fatty acid derived from prostaglandin E1 that activates type-2 chloride (ClC-2) channels on the apical membrane of intestinal epithelial cells. Chloride efflux into the lumen draws water secondarily, increasing intraluminal fluid and accelerating transit. Its main adverse effect is nausea, reduced by taking it with food.
Option A: Option A is incorrect. 5-HT3 receptor blockade describes alosetron, not lubiprostone.
Option B: Option B is incorrect. Bile acid sequestration describes cholestyramine and related resins.
Option C: Option C is incorrect. Peripheral mu-opioid receptor antagonism describes the PAMORAs used for opioid-induced constipation.
Option D: Option D is incorrect. Fermentation to gases that draw water osmotically describes lactulose, not the chloride-channel mechanism of lubiprostone.
6. A patient on chronic opioid therapy develops constipation that responds poorly to standard laxatives. Which mechanism best explains opioid-induced constipation (OIC)?
A) Opioids bind mu-opioid receptors in the myenteric and submucosal plexuses, reducing propulsive motility, decreasing secretion, and increasing sphincter tone
B) Opioids inhibit the cystic fibrosis transmembrane conductance regulator (CFTR) channel, blocking chloride secretion
C) Opioids deplete colonic bacteria, eliminating the fermentation needed for normal stool bulk
D) Opioids directly inhibit the sodium/hydrogen exchanger isoform 3 (NHE3) in the colon
E) Opioids antagonize 5-hydroxytryptamine type 4 (5-HT4) receptors that normally promote motility
ANSWER: A
Rationale:
Option A is correct. Opioid analgesics bind mu-opioid receptors concentrated in the myenteric and submucosal plexuses of the enteric nervous system. The result is reduced propulsive motility, increased non-propulsive segmental contractions, decreased intestinal secretion, and increased anal sphincter tone. The enteric nervous system holds the highest density of mu-opioid receptors outside the central nervous system, which is why conventional laxatives are frequently inadequate.
Option B: Option B is incorrect. CFTR inhibition is not the OIC mechanism; CFTR is the secretory channel activated downstream of GC-C agonists.
Option C: Option C is incorrect. OIC is receptor-mediated, not the result of microbiome depletion.
Option D: Option D is incorrect. NHE3 is the target of tenapanor; opioids do not produce constipation through NHE3 inhibition.
Option E: Option E is incorrect. Opioids do not cause constipation by antagonizing 5-HT4 receptors; the mechanism is mu-opioid receptor agonism in the gut wall.
7. Peripherally acting mu-opioid receptor antagonists (PAMORAs) relieve opioid-induced constipation without reversing the analgesia the patient needs. What property allows this selectivity?
A) They are partial agonists that only weakly activate central opioid receptors
B) They are metabolized to inactive forms before reaching the central nervous system
C) They are largely excluded from the central nervous system at the blood-brain barrier, by molecular charge or P-glycoprotein efflux, confining antagonism to gut receptors
D) They bind only delta-opioid receptors, sparing the mu receptors that mediate analgesia
E) They act exclusively on 5-hydroxytryptamine type 3 (5-HT3) receptors rather than opioid receptors
ANSWER: C
Rationale:
Option C is correct. PAMORAs are designed so that they are largely kept out of the central nervous system at the blood-brain barrier. Methylnaltrexone carries a quaternary nitrogen whose positive charge limits penetration; naloxegol is PEGylated and is a P-glycoprotein substrate; naldemedine has a bulky side chain that reduces entry. Their mu-opioid antagonism is therefore confined to peripheral receptors in the gut, relieving constipation without reversing central analgesia.
Option A: Option A is incorrect. PAMORAs are antagonists, not partial agonists, and their selectivity comes from CNS exclusion rather than weak central activation.
Option B: Option B is incorrect. Selectivity is due to restricted CNS entry, not metabolic inactivation before reaching the brain.
Option D: Option D is incorrect. PAMORAs antagonize peripheral mu-opioid receptors; they are not delta-selective.
Option E: Option E is incorrect. PAMORAs act at opioid receptors, not 5-HT3 receptors.
8. Loperamide is a synthetic opioid agonist, yet at standard doses it relieves diarrhea without producing euphoria, analgesia, or other central opioid effects. Which property best explains this?
A) It is a competitive antagonist at peripheral mu-opioid receptors
B) It is a high-affinity P-glycoprotein substrate that is pumped out at the blood-brain barrier, keeping central nervous system levels negligible at standard doses
C) It binds only kappa-opioid receptors, which do not mediate central effects
D) It is destroyed by gastric acid before any systemic absorption can occur
E) It acts solely by osmotically retaining water in the colon
ANSWER: B
Rationale:
Option B is correct. Loperamide is a potent mu-opioid receptor agonist in the myenteric plexus, slowing transit and reducing secretion, but it is also an extremely high-affinity P-glycoprotein substrate at the blood-brain barrier. Efflux keeps central nervous system concentrations negligible at standard doses, so it produces antidiarrheal action without central opioid effects. At supratherapeutic (misuse) doses, P-glycoprotein efflux can saturate, allowing cardiac sodium- and potassium-channel effects with QT prolongation and dangerous arrhythmias.
Option A: Option A is incorrect. Loperamide is an agonist at gut mu-opioid receptors, not an antagonist.
Option C: Option C is incorrect. Its antidiarrheal action is mediated through mu-opioid receptors, not kappa selectivity.
Option D: Option D is incorrect. Loperamide is not simply destroyed by gastric acid; its peripheral selectivity is due to P-glycoprotein efflux at the blood-brain barrier.
Option E: Option E is incorrect. Loperamide works by slowing motility and reducing secretion through opioid receptors, not by osmotic water retention.
9. Oral vancomycin is a standard treatment for Clostridioides difficile infection (CDI), yet it is given orally even though it is used intravenously for systemic infections. Which property explains why the oral route works for CDI and avoids the toxicity seen with systemic use?
A) Oral vancomycin is rapidly absorbed and concentrated by the liver into bile delivered to the colon
B) Oral vancomycin is converted by colonic bacteria into a more active metabolite
C) Oral vancomycin crosses the inflamed colonic mucosa to reach systemic circulation, then re-enters the lumen
D) Oral vancomycin is minimally absorbed from the gut, achieving very high intraluminal stool concentrations while producing negligible systemic exposure and avoiding nephrotoxicity and ototoxicity
E) Oral vancomycin neutralizes toxin B directly in the bloodstream
ANSWER: D
Rationale:
Option D is correct. Given orally, vancomycin is minimally absorbed from the gastrointestinal tract, so it reaches very high concentrations in stool (well above the levels needed to kill C. difficile) while systemic exposure stays negligible. This avoids the nephrotoxicity and ototoxicity associated with intravenous vancomycin and delivers drug exactly where the infection resides, in the colonic lumen.
Option A: Option A is incorrect. Efficacy does not depend on hepatic concentration and biliary delivery; it depends on poor oral absorption keeping drug in the lumen.
Option B: Option B is incorrect. Vancomycin is not a prodrug requiring bacterial conversion in the colon.
Option C: Option C is incorrect. The mechanism is the opposite of systemic recirculation; the drug stays in the lumen because it is poorly absorbed.
Option E: Option E is incorrect. Direct neutralization of toxin B describes the monoclonal antibody bezlotoxumab, not vancomycin.
10. A 70-year-old man with advanced chronic kidney disease asks about using magnesium citrate for occasional constipation. Why is a magnesium-containing laxative a poor choice in this patient compared with PEG?
A) Magnesium salts have no laxative effect once kidney function declines
B) Magnesium is partially absorbed, and impaired renal excretion can lead to magnesium accumulation and toxicity
C) Magnesium salts are metabolized to a hepatotoxic compound in patients with kidney disease
D) Magnesium salts bind PEG, neutralizing both agents in the lumen
E) Magnesium salts require intact colonic bacteria, which are depleted in kidney disease
ANSWER: B
Rationale:
Option B is correct. Magnesium salts act osmotically and also stimulate cholecystokinin release to increase motility, but magnesium is partially absorbed. In patients with renal impairment, reduced renal magnesium excretion allows magnesium to accumulate, risking hypermagnesemia and toxicity. PEG, which is essentially not absorbed and causes no significant electrolyte shifts, is preferred in this setting.
Option A: Option A is incorrect. Magnesium salts retain their osmotic laxative effect in renal disease; the problem is systemic accumulation, not loss of efficacy.
Option C: Option C is incorrect. The concern is magnesium accumulation, not conversion to a hepatotoxin.
Option D: Option D is incorrect. Magnesium does not bind or neutralize PEG.
Option E: Option E is incorrect. The osmotic action of magnesium does not depend on colonic bacteria, and the hazard in CKD is magnesium retention.
11. A hospitalized patient develops profuse watery diarrhea with fever after a course of broad-spectrum antibiotics, and Clostridioides difficile infection (CDI) is suspected. The intern considers loperamide for symptom relief. Why is loperamide contraindicated here?
A) Loperamide accelerates colonic transit and would worsen diarrhea
B) Loperamide is inactivated by the alkaline colonic environment in CDI
C) Loperamide directly stimulates C. difficile toxin production
D) Loperamide is only effective for osmotic, not secretory, diarrhea
E) By suppressing the motility that helps clear toxin and pathogen, loperamide can precipitate toxic megacolon in CDI
ANSWER: E
Rationale:
Option E is correct. In CDI and other invasive or dysenteric diarrheas, propulsive motility helps clear toxin and organisms. Loperamide slows that motility, which can promote toxin retention and precipitate toxic megacolon. For this reason it is contraindicated in confirmed or suspected CDI and in dysenteric diarrhea with blood, mucus, or high fever.
Option A: Option A is incorrect. Loperamide slows transit; it does not accelerate it.
Option B: Option B is incorrect. Loperamide is not inactivated by colonic pH in CDI; the hazard is its motility-suppressing effect.
Option C: Option C is incorrect. Loperamide does not stimulate toxin production; the risk arises from reduced clearance and dysmotility.
Option D: Option D is incorrect. Loperamide is effective across functional and secretory diarrheas; the issue is the danger of using it when an invasive process such as CDI is present.
12. In the treatment of non-severe Clostridioides difficile infection (CDI), fidaxomicin is now preferred over oral vancomycin in major guidelines largely because of one clinical advantage. What is it, and what explains it?
A) Lower recurrence rates, attributed to fidaxomicin's narrow spectrum sparing colonization-resistance flora such as Bacteroides
B) Faster initial clinical cure because of superior systemic absorption
C) Activity against hypervirulent NAP1 (ribotype 027) strains that vancomycin lacks
D) Lower cost, making it the most economical first-line option
E) Ability to be dosed once weekly because of its long systemic half-life
ANSWER: A
Rationale:
Option A is correct. In two phase 3 trials, fidaxomicin produced clinical cure rates similar to oral vancomycin but significantly lower recurrence for non-hypervirulent strains. The advantage is attributed to its narrow spectrum and relative sparing of Bacteroides and other organisms that maintain colonization resistance, which vancomycin suppresses. It is minimally absorbed and concentrated in the colon.
Option B: Option B is incorrect. Fidaxomicin is minimally absorbed, and cure rates are similar to vancomycin rather than faster from systemic absorption.
Option C: Option C is incorrect. The recurrence advantage is not seen in hypervirulent NAP1/ribotype 027 strains.
Option D: Option D is incorrect. Cost is a limiting factor for fidaxomicin, not an advantage.
Option E: Option E is incorrect. Fidaxomicin is given twice daily and acts locally in the colon; it is not a once-weekly systemic agent.
13. Linaclotide and plecanatide are used in irritable bowel syndrome with constipation (IBS-C) and provide both a laxative and an analgesic benefit. Which mechanism accounts for both effects?
A) Antagonism of 5-hydroxytryptamine type 3 (5-HT3) receptors on afferent neurons
B) Inhibition of the sodium/hydrogen exchanger isoform 3 (NHE3) reducing sodium absorption
C) Agonism at guanylate cyclase-C (GC-C) receptors raising intracellular cyclic guanosine monophosphate (cGMP), which activates CFTR-driven fluid secretion and also inhibits submucosal pain-sensing neurons
D) Direct activation of type-2 chloride (ClC-2) channels on the apical epithelial membrane
E) Sequestration of bile acids that would otherwise stimulate colonic secretion
ANSWER: C
Rationale:
Option C is correct. Linaclotide and plecanatide are guanylate cyclase-C (GC-C) agonists that mimic the endogenous ligands guanylin and uroguanylin. GC-C activation raises intracellular cyclic guanosine monophosphate (cGMP), which activates the cystic fibrosis transmembrane conductance regulator (CFTR), driving chloride and bicarbonate secretion into the lumen. The same cGMP signal directly inhibits submucosal pain-sensing neurons, which is why these agents reduce IBS pain beyond their prokinetic effect. Both have negligible systemic absorption.
Option A: Option A is incorrect. 5-HT3 antagonism describes alosetron, not GC-C agonists.
Option B: Option B is incorrect. NHE3 inhibition describes tenapanor, which lacks the direct analgesic effect of GC-C agonists.
Option D: Option D is incorrect. ClC-2 channel activation describes lubiprostone.
Option E: Option E is incorrect. Bile acid sequestration describes cholestyramine, not these secretagogues.
14. A patient on naloxegol for opioid-induced constipation is about to start clarithromycin for a respiratory infection. Why does this combination require attention?
A) Clarithromycin displaces naloxegol from plasma proteins, lowering its effect
B) Clarithromycin and naloxegol both prolong the QT interval, summing to a dangerous degree
C) Clarithromycin induces naloxegol metabolism, causing loss of constipation control
D) Naloxegol is a CYP3A4 substrate, and strong CYP3A4 inhibitors such as clarithromycin are contraindicated because they raise naloxegol exposure and the risk of central effects
E) Clarithromycin chelates naloxegol in the gut lumen, blocking absorption of both
ANSWER: D
Rationale:
Option D is correct. Naloxegol is metabolized by CYP3A4. Strong CYP3A4 inhibitors such as clarithromycin and ketoconazole markedly increase naloxegol plasma concentrations, raising the risk of central nervous system exposure and potential opioid withdrawal; they are therefore contraindicated. Moderate inhibitors require dose reduction (for example to 12.5 mg daily).
Option A: Option A is incorrect. The interaction is metabolic (CYP3A4 inhibition), not protein-binding displacement.
Option B: Option B is incorrect. The clinically relevant concern is elevated naloxegol exposure from CYP3A4 inhibition, not additive QT prolongation.
Option C: Option C is incorrect. Clarithromycin inhibits rather than induces CYP3A4, so naloxegol levels rise, not fall.
Option E: Option E is incorrect. The interaction is not luminal chelation; it is inhibition of naloxegol's hepatic metabolism.
15. Bismuth subsalicylate is useful for traveler's diarrhea, but the salicylate component carries safety implications. Which precaution follows directly from that salicylate content?
A) It should be avoided in patients with renal impairment because bismuth accumulates
B) It should not be given to children or teenagers with viral illnesses because of Reye syndrome risk, and it interacts with anticoagulants
C) It should be taken only with food because the salicylate causes nausea in most patients
D) It must be separated from all other oral drugs by at least four hours because salicylate binds them in the lumen
E) It should be avoided in patients with hypertension because salicylate raises blood pressure
ANSWER: B
Rationale:
Option B is correct. The salicylate component of bismuth subsalicylate is systemically absorbed and represents a clinically meaningful salicylate dose. As with aspirin, it should not be given to children or teenagers with viral illnesses because of the risk of Reye syndrome, and it can interact with anticoagulants such as warfarin. Patients should also be told that bismuth sulfide formation turns the stool and tongue black, which is harmless but can be mistaken for GI bleeding.
Option A: Option A is incorrect. The defining precaution stems from the salicylate moiety; renal bismuth accumulation is not the principal teaching point here.
Option C: Option C is incorrect. Taking it with food is not the salicylate-driven safety issue; Reye syndrome and anticoagulant interaction are.
Option D: Option D is incorrect. Four-hour separation from other drugs describes cholestyramine, not bismuth subsalicylate.
Option E: Option E is incorrect. Salicylate in bismuth subsalicylate is not characterized by raising blood pressure as its key precaution.
16. A patient with diarrhea-predominant irritable bowel syndrome (IBS-D) who had a cholecystectomy years ago is being considered for eluxadoline. Why is eluxadoline contraindicated in this patient?
A) Without a gallbladder, eluxadoline carries a significant risk of sphincter of Oddi spasm leading to acute pancreatitis
B) Eluxadoline requires gallbladder bile flow for activation, so it would be ineffective
C) Eluxadoline accumulates to toxic levels in patients who have had a cholecystectomy
D) Eluxadoline antagonizes mu-opioid receptors, worsening diarrhea after cholecystectomy
E) Eluxadoline is contraindicated only in patients with an intact gallbladder, not after cholecystectomy
ANSWER: A
Rationale:
Option A is correct. Eluxadoline is a mixed opioid receptor modulator (mu- and kappa-agonist, delta-antagonist) acting largely in the enteric nervous system. In patients without a gallbladder, unopposed mu-opioid agonism at the sphincter of Oddi after loss of gallbladder-mediated bile flow regulation can cause sphincter spasm and acute pancreatitis, so it is contraindicated post-cholecystectomy. It is also contraindicated with biliary obstruction, alcoholism, or heavy alcohol use.
Option B: Option B is incorrect. Eluxadoline does not depend on gallbladder bile flow for activation; the issue is the danger of sphincter of Oddi spasm.
Option C: Option C is incorrect. The hazard is sphincter spasm and pancreatitis, not systemic drug accumulation, since eluxadoline is minimally absorbed.
Option D: Option D is incorrect. Eluxadoline is a mu-opioid agonist (not antagonist), which slows motility; the contraindication is pancreatitis risk.
Option E: Option E is incorrect. The contraindication applies specifically to patients lacking a gallbladder, which is the reverse of this statement.
17. For decades metronidazole was first-line for Clostridioides difficile infection (CDI), but current IDSA/SHEA guidelines no longer recommend it as first-line for any severity. What is the primary reason for this change?
A) Metronidazole was found to be teratogenic and is now avoided in all adults
B) Metronidazole is no longer manufactured in an oral formulation
C) Metronidazole achieves excessive colonic concentrations, causing mucosal toxicity
D) Metronidazole now has FDA-mandated REMS restrictions limiting its use
E) Head-to-head data showed inferior clinical cure and higher recurrence compared with oral vancomycin, especially in non-severe disease
ANSWER: E
Rationale:
Option E is correct. Metronidazole was downgraded because head-to-head trials demonstrated inferior clinical cure rates and higher recurrence compared with oral vancomycin, particularly for non-severe CDI. It is now reserved as an alternative only when vancomycin and fidaxomicin are unavailable or cost-prohibitive, and intravenous metronidazole still has a role combined with oral vancomycin in fulminant disease.
Option A: Option A is incorrect. The downgrade reflects comparative efficacy data in CDI, not a new teratogenicity finding driving avoidance in all adults.
Option B: Option B is incorrect. Oral metronidazole remains available; availability is not the reason.
Option C: Option C is incorrect. The issue is inferior efficacy and higher recurrence, not colonic mucosal toxicity from excessive concentration.
Option D: Option D is incorrect. Metronidazole's downgrade is not due to a REMS program; REMS applies to drugs such as alosetron.
18. A patient has had multiple recurrences of Clostridioides difficile infection (CDI) despite appropriate antibiotic courses. Fecal microbiota transplant (FMT) is recommended. What is the underlying rationale for FMT in recurrent CDI?
A) FMT delivers high-dose donor antibiotics directly into the colon
B) FMT supplies neutralizing antibodies against toxin B in donor stool
C) FMT restores a diverse microbiome that re-establishes colonization resistance, competitively excluding C. difficile
D) FMT acidifies the colonic lumen to a pH that kills C. difficile spores
E) FMT permanently sterilizes the colon, preventing any future bacterial colonization
ANSWER: C
Rationale:
Option C is correct. Recurrent CDI reflects persistent microbiome depletion that lets C. difficile re-establish after each antibiotic course. FMT transfers screened donor stool to reconstitute a diverse microbiome, restoring colonization resistance so that C. difficile is competitively excluded. Randomized trials show resolution rates of roughly 80 to 90 percent, well above antibiotics alone, and standardized products (Rebyota, Vowst) are now FDA-approved.
Option A: Option A is incorrect. FMT works by microbiome restoration, not by delivering donor antibiotics.
Option B: Option B is incorrect. Toxin B neutralization by antibody describes bezlotoxumab, not FMT.
Option D: Option D is incorrect. FMT does not act by acidifying the lumen to kill spores; the lumen is repopulated with healthy flora.
Option E: Option E is incorrect. FMT restores a healthy diverse flora rather than sterilizing the colon; permanent sterilization would itself remove colonization resistance.
19. Alosetron is available only through a restricted Risk Evaluation and Mitigation Strategy (REMS) program. Which combination of mechanism and safety concern explains these restrictions?
A) It is a guanylate cyclase-C (GC-C) agonist with a black box warning against use in infants
B) It is a 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist that slows colonic transit, with serious risks of ischemic colitis and severe constipation
C) It is a mu-opioid receptor antagonist with a risk of opioid withdrawal
D) It is a type-2 chloride (ClC-2) channel activator with a high incidence of nausea
E) It is a sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor with a risk of hyperphosphatemia
ANSWER: B
Rationale:
Option B is correct. Alosetron is a potent, selective 5-HT3 receptor antagonist. Blocking 5-HT3 receptors on GI afferent neurons slows colonic transit, increases compliance, and reduces visceral pain in IBS-D. It was withdrawn shortly after approval because of ischemic colitis (about 1 in 1,000 patients per year) and severe constipation, then reintroduced under a REMS program restricted to women with severe IBS-D unresponsive to conventional therapy.
Option A: Option A is incorrect. GC-C agonists with an infant black box warning are linaclotide and plecanatide, not alosetron.
Option C: Option C is incorrect. Mu-opioid receptor antagonism with withdrawal risk describes the PAMORAs.
Option D: Option D is incorrect. ClC-2 channel activation with prominent nausea describes lubiprostone.
Option E: Option E is incorrect. NHE3 inhibition relates to tenapanor; hyperphosphatemia is an approved indication for tenapanor, not a risk that drives an alosetron REMS.
20. A patient with diarrhea-predominant irritable bowel syndrome (IBS-D) and prominent abdominal pain is started on low-dose amitriptyline at bedtime. The physician explains it is being used for pain, not depression. Which statement best captures why a low-dose tricyclic antidepressant (TCA) is rational here?
A) At low doses the TCA acts as a stimulant laxative, relieving constipation that accompanies IBS-D
B) The TCA works only at full antidepressant doses, so the low dose is a starting titration step toward mood treatment
C) The TCA accelerates colonic transit, which is the desired effect in IBS-D
D) The TCA reduces visceral afferent signaling and enhances descending pain inhibition, and its transit-slowing effect is a useful side benefit in IBS-D
E) The TCA antagonizes guanylate cyclase-C (GC-C) receptors, reducing secretion
ANSWER: D
Rationale:
Option D is correct. Low-dose TCAs target visceral hypersensitivity rather than mood, reducing visceral afferent signaling (in part through sodium-channel blockade on sensory afferents and antihistamine effects) and enhancing descending pain inhibition. Their anticholinergic transit-slowing effect is an advantageous side benefit in IBS-D, where slower transit counters diarrhea. The analgesic effect occurs at doses well below antidepressant doses, which is why patients should be counseled the indication is pain modulation.
Option A: Option A is incorrect. TCAs are not stimulant laxatives, and IBS-D involves diarrhea, not constipation needing a laxative.
Option B: Option B is incorrect. The analgesic benefit appears at low doses and is mechanistically independent of the antidepressant effect; it is not merely a titration step.
Option C: Option C is incorrect. TCAs slow transit; acceleration of transit (more useful in IBS-C) is associated with SSRIs.
Option E: Option E is incorrect. GC-C antagonism is not a TCA mechanism; GC-C agonism describes linaclotide and plecanatide.
21. A patient with bile acid diarrhea after ileal resection is prescribed cholestyramine. She also takes levothyroxine, warfarin, and digoxin. What counseling point is essential to avoid a drug interaction?
A) Other medications should be taken at least 1 to 2 hours before or 4 hours after cholestyramine, because it binds many co-administered drugs in the lumen
B) Cholestyramine should be taken on an empty stomach to enhance its systemic absorption
C) Cholestyramine should be stopped whenever any antibiotic is prescribed, because it inactivates antibiotics systemically
D) All fat-soluble vitamins should be discontinued permanently while on cholestyramine
E) Cholestyramine doses should be doubled when taken with warfarin to maintain efficacy
ANSWER: A
Rationale:
Option A is correct. Cholestyramine is a non-absorbed anion-exchange resin that binds bile acids in the lumen, but it also binds numerous co-administered drugs, including thyroxine, warfarin, digoxin, fat-soluble vitamins, and certain antibiotics. To preserve absorption of those agents, other medications should be taken at least 1 to 2 hours before or 4 hours after cholestyramine.
Option B: Option B is incorrect. Cholestyramine acts in the lumen and is not meant to be systemically absorbed; empty-stomach dosing to boost absorption is not the issue.
Option C: Option C is incorrect. The concern is luminal binding that reduces absorption of co-administered drugs, addressed by separating doses, not by stopping cholestyramine for any antibiotic, and it does not inactivate antibiotics systemically.
Option D: Option D is incorrect. Fat-soluble vitamins can be continued but should be dose-separated; permanent discontinuation is not required.
Option E: Option E is incorrect. Doubling cholestyramine alongside warfarin would worsen binding and is not appropriate; dose separation is the correct approach.
22. During treatment of a high-risk Clostridioides difficile infection (CDI), bezlotoxumab is added. How does bezlotoxumab work, and what important safety warning applies?
A) It is an antibiotic that directly kills C. difficile, with a warning for nephrotoxicity
B) It is a 5-hydroxytryptamine type 3 (5-HT3) antagonist that slows transit, with a warning for ischemic colitis
C) It is a monoclonal antibody that neutralizes C. difficile toxin B to reduce recurrence, with a black box warning for heart failure exacerbation
D) It is an osmotic agent that clears toxin from the colon, with a warning for electrolyte disturbance
E) It is a peripherally acting mu-opioid antagonist, with a warning for opioid withdrawal
ANSWER: C
Rationale:
Option C is correct. Bezlotoxumab is a human monoclonal antibody directed against C. difficile toxin B (TcdB), given as a single intravenous infusion during antibiotic treatment. It does not treat active infection but neutralizes TcdB to reduce recurrence, with the greatest benefit in high-risk patients. It carries a black box warning for heart failure exacerbation and should be used cautiously in patients with pre-existing heart failure.
Option A: Option A is incorrect. Bezlotoxumab is not an antibiotic and does not kill the organism; it neutralizes toxin B.
Option B: Option B is incorrect. A 5-HT3 antagonist with ischemic colitis risk describes alosetron.
Option D: Option D is incorrect. Bezlotoxumab is a toxin-neutralizing antibody, not an osmotic agent.
Option E: Option E is incorrect. A peripherally acting mu-opioid antagonist with withdrawal risk describes the PAMORAs, not bezlotoxumab.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.